 Multiple Sclerosis, Relapsing-Remitting
"Multiple Sclerosis, Relapsing-Remitting" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The most common clinical variant of MULTIPLE SCLEROSIS, characterized by recurrent acute exacerbations of neurologic dysfunction followed by partial or complete recovery. Common clinical manifestations include loss of visual (see OPTIC NEURITIS), motor, sensory, or bladder function. Acute episodes of demyelination may occur at any site in the central nervous system, and commonly involve the optic nerves, spinal cord, brain stem, and cerebellum. (Adams et al., Principles of Neurology, 6th ed, pp903-914)
| Descriptor ID |
D020529
|
| MeSH Number(s) |
C10.114.375.500.600 C10.314.350.500.600 C20.111.258.250.500.600
|
| Concept/Terms |
Multiple Sclerosis, Relapsing-Remitting- Multiple Sclerosis, Relapsing-Remitting
- Multiple Sclerosis, Relapsing Remitting
- Remitting-Relapsing Multiple Sclerosis
- Multiple Sclerosis, Remitting-Relapsing
- Remitting Relapsing Multiple Sclerosis
- Relapsing-Remitting Multiple Sclerosis
- Relapsing Remitting Multiple Sclerosis
|
Below are MeSH descriptors whose meaning is more general than "Multiple Sclerosis, Relapsing-Remitting".
Below are MeSH descriptors whose meaning is more specific than "Multiple Sclerosis, Relapsing-Remitting".
This graph shows the total number of publications written about "Multiple Sclerosis, Relapsing-Remitting" by people in this website by year, and whether "Multiple Sclerosis, Relapsing-Remitting" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 1 | 0 | 1 | | 2004 | 3 | 0 | 3 | | 2005 | 1 | 0 | 1 | | 2008 | 1 | 0 | 1 | | 2009 | 3 | 0 | 3 | | 2012 | 3 | 0 | 3 | | 2013 | 2 | 0 | 2 | | 2014 | 1 | 0 | 1 | | 2015 | 7 | 0 | 7 | | 2016 | 2 | 0 | 2 | | 2017 | 4 | 0 | 4 | | 2018 | 3 | 0 | 3 | | 2019 | 4 | 0 | 4 | | 2020 | 2 | 0 | 2 | | 2021 | 3 | 2 | 5 | | 2022 | 3 | 1 | 4 | | 2023 | 1 | 0 | 1 | | 2024 | 1 | 1 | 2 | | 2025 | 3 | 0 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Multiple Sclerosis, Relapsing-Remitting" by people in Profiles.
-
Chang G, Sebastian P, Virupakshaiah A, Schoeps VA, Cherbuin N, Casper TC, Gorman MP, Benson LA, Chitnis T, Rensel M, Abrams AW, Lotze T, Mar SS, Schreiner TL, Wheeler YS, Rose JW, Graves J, Krupp LB, Waldman AT, Lucas R, Waubant E. Association Between Sun Exposure and Risk of Relapse in Pediatric-Onset Multiple Sclerosis. Neurol Neuroimmunol Neuroinflamm. 2025 Mar; 12(2):e200375.
-
Corboy JR, Fox RJ, Cutter G, Engebretson E, Miller A, Morgan C, Gustafson T, Goodman AD, Kannan M, Sriram S, Xia Z, Lynch S, Bowen J, Kister I. DISCOntinuation of disease-modifying therapies in MS: The DISCOMS extension trial. Mult Scler. 2025 Feb; 31(2):159-173.
-
Mar S, Valeriani M, Steinborn B, Schreiner T, Waubant E, Filippi M, Kotulska K, Mazurkiewicz-Beldzinska M, El Azzouzi B, Lin CJ, Shen YA, Kletzl H, Evershed J, Hogea A, Manlius C, Bonati U, Banwell B. Ocrelizumab dose selection for treatment of pediatric relapsing-remitting multiple sclerosis: results of the OPERETTA I study. J Neurol. 2025 Jan 15; 272(2):137.
-
Johnson KA, Bandera VM, Diehl M, Leach HJ, Fling BW. Walking performance differs between people with multiple sclerosis who perform distinct types of exercise. Neurodegener Dis Manag. 2024; 14(3-4):75-85.
-
Wolf AB, Alvarez E, Corboy JR. Comparative Efficacy of Disease-Modifying Treatments for Relapsing Multiple Sclerosis-Variations in Real-World Experience. JAMA Neurol. 2024 Jan 01; 81(1):87.
-
Zhou W, Graner M, Beseler C, Domashevich T, Selva S, Webster G, Ledreux A, Zizzo Z, Lundt M, Alvarez E, Yu X. Plasma IgG aggregates as biomarkers for multiple sclerosis. Clin Immunol. 2023 11; 256:109801.
-
Curran C, Vaitaitis G, Waid D, Volmer T, Alverez E, Wagner DH. Ocrevus reduces TH40 cells, a biomarker of systemic inflammation, in relapsing multiple sclerosis (RMS) and in progressive multiple sclerosis (PMS). J Neuroimmunol. 2023 Jan 15; 374:578008.
-
Nair KV. Role of the Bruton tyrosine kinase pathway in multiple sclerosis. Am J Manag Care. 2022 12; 28(16 Suppl):S323-S328.
-
Steinman L, Fox E, Hartung HP, Alvarez E, Qian P, Wray S, Robertson D, Huang D, Selmaj K, Wynn D, Cutter G, Mok K, Hsu Y, Xu Y, Weiss MS, Bosco JA, Power SA, Lee L, Miskin HP, Cree BAC. Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis. N Engl J Med. 2022 08 25; 387(8):704-714.
-
Ntranos A, Park HJ, Wentling M, Tolstikov V, Amatruda M, Inbar B, Kim-Schulze S, Frazier C, Button J, Kiebish MA, Lublin F, Edwards K, Casaccia P. Bacterial neurotoxic metabolites in multiple sclerosis cerebrospinal fluid and plasma. Brain. 2022 04 18; 145(2):569-583.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|